#USA #Singapore #George Clinical #Clinical Research #Emerald Trials

George Clinical Rebrands as Emerald Clinical Trials

In a strategic move, George Clinical, a leading global clinical research organization (CRO), has announced its rebranding to Emerald Clinical Trials. This name change reflects the company's growth and commitment to enhancing certainty and transparency in clinical research worldwide. With over 20 years of experience, Emerald Clinical Trials positions itself as a reliable and flexible player in the clinical development space, emphasizing its local and therapeutic expertise to mitigate global risks.

The rebranded company will continue to provide comprehensive services across various therapeutic areas, focusing on improving lives and driving innovation in global clinical research protocols. With extensive knowledge in oncology and cardio-renal metabolic therapies, Emerald Clinical Trials is uniquely differentiated in the global clinical CRO landscape. The organization has a remarkable reach, with direct representation in 42 countries and partnerships in an additional 70, enabling seamless execution of clinical studies around the globe.

The new brand identity underscores the extensive experience and capabilities that Emerald Clinical Trials can now offer a much broader audience. It also highlights the organization’s strong commitment to patients, customers, and partners in the clinical trial ecosystem. The company’s customer-centric approach fosters long-term relationships based on trust, reliability, and measurable success, as demonstrated by the loyalty of its clients and recognition for excellence in the industry.

"For the last two decades, Emerald Clinical Trials has focused on delivering high-quality studies that combine global reach with a highly personalized approach. We offer the scale and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, whether from emerging biotech firms or top-tier pharmaceutical companies, receives the targeted support they need to mitigate clinical program risks," said Mary Gunn, Chief Executive Officer of Emerald Clinical Trials. "This remarkable transformation will solidify our position as a trusted partner in clinical research and reaffirm our commitment to our clients and core values."

Dr. Daniel Tillett, CEO of Race Oncology, a client of Emerald, reflects, "From the beginning, we have known we wanted to work with a flexible CRO offering solutions tailored to the specific needs of each study—whether that means accelerating timelines, adapting to new requirements, or effectively scaling resources. For biopharmaceutical companies looking for a partner that can keep pace without falling back on bureaucratic issues, agility is key. That is the fundamental asset of Emerald Clinical Trials."

Emerald Clinical Trials is a preeminent clinical research organization with a worldwide presence, servicing over 100 biotech firms and 6 of the top 10 pharmaceutical companies. With its headquarters in Singapore, the organization relies on operational expertise and cutting-edge scientific knowledge to provide comprehensive clinical evaluation services to clients across the globe, offering solutions at every stage of the assessment process.

For further information about this transformation and the services offered, visit Emerald Clinical Trials.
Media Contact: Shannon Severino, [email protected], Tel. +1 412 608 2393